hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06292026, orgStudyIdInfo id: DFU/1, briefTitle: Efficacy of ProgenaMatrix™ in the Management of DFUs, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2022-03-14, primaryCompletionDateStruct date: 2026-03, completionDateStruct date: 2026-09, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: ProgenaCare Global, LLC, class: INDUSTRY, descriptionModule briefSummary: This multicenter study will collect data to determine closure time for diabetic ulcers when following protocol parameters and treatment with ProgenaMatrix™., conditionsModule conditions: Diabetic Foot Ulcer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: The objective of this data collection is to look at outcomes and time points for ProgenaMatrix™ in the treatment of diabetic foot ulcers. Additionally, use the collected data to develop predictive wound closure models. There is a 1-week lead in period after initial debridement. If the wound is rapidly moving to closure after initial debridement and standard moist dressings, the withdrawal of these patients will prevent corruption of the true closure rate of ProgenaMatrix™. The objective of the treatment with ProgenaMatrix™ is to evaluate the closure rate in patients not responding to traditional moist therapy., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ACTUAL, armsInterventionsModule interventions name: ProgenaMatrix Keratin graft, interventions name: standard of care, outcomesModule primaryOutcomes measure: time to wound closure, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: United Wound Healing, city: Puyallup, state: Washington, zip: 98371, country: United States, geoPoint lat: 47.18538, lon: -122.2929, hasResults: False
protocolSection identificationModule nctId: NCT06291987, orgStudyIdInfo id: IRB23-1681, briefTitle: Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation, acronym: MPN, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-20, primaryCompletionDateStruct date: 2026-05, completionDateStruct date: 2026-05, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: University of Chicago, class: OTHER, descriptionModule briefSummary: The purpose of this research is to gather information on the safety and effectiveness determining maximum tolerated dose (MTD) of ruxolitinib in combination with ivosidenib in IDH1-mutated advanced-phase Ph-negative MPNs while evaluate the efficacy of ruxolitinib in combination with ivosidenib in IDH1-mutated advanced-phase Ph-negative MPNs., conditionsModule conditions: Myeloproliferative Neoplasms, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 18, type: ESTIMATED, armsInterventionsModule interventions name: Ivosidenib, interventions name: Ruxolitinib, outcomesModule primaryOutcomes measure: Maximum tolerated dose, secondaryOutcomes measure: Overall Survival (OS), secondaryOutcomes measure: Overall Response Rate (ORR), secondaryOutcomes measure: Time to Response (TTR), secondaryOutcomes measure: Duration of response (DOR), secondaryOutcomes measure: Progression free survival (PFS), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Chicago Medicine Comprehensive Cancer Center, city: Chicago, state: Illinois, zip: 60637, country: United States, contacts name: Clinical Trials Intake, role: CONTACT, phone: 855-702-8222, email: cancerclinicaltrials@bsd.uchicago.edu, contacts name: Anand Patel, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 41.85003, lon: -87.65005, hasResults: False
protocolSection identificationModule nctId: NCT06291974, orgStudyIdInfo id: delta2024, briefTitle: Ankle Foot Orthosis on Muscle Activity in Cerebral Palsy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2024-10-15, completionDateStruct date: 2024-11-30, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Delta University for Science and Technology, class: OTHER, descriptionModule briefSummary: To compare the effect of solid ankle foot orthosis and ground reaction foot orthosis on the muscle activity in children with spastic diplegic cerebral palsy (Gross Motor Functional Classification Scale III)., conditionsModule conditions: Cerebral Palsy Spastic Diplegia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: electromyography, outcomesModule primaryOutcomes measure: muscle activity by Electromyography device, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 12 Years, stdAges: CHILD, hasResults: False
protocolSection identificationModule nctId: NCT06291961, orgStudyIdInfo id: CS-101-01, briefTitle: A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2025-05, completionDateStruct date: 2025-07, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: CorrectSequence Therapeutics Co., Ltd, class: INDUSTRY, descriptionModule briefSummary: The goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 in treating patients with β-thalassemia major anemia., conditionsModule conditions: Beta-Thalassemia Major, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 8, type: ESTIMATED, armsInterventionsModule interventions name: CS-101 injection, outcomesModule primaryOutcomes measure: AEs(Adverse Events) and SAEs(Serious Adverse Events) after CS-101 infusion, primaryOutcomes measure: Overall survival rate, primaryOutcomes measure: Proportion of subjects with engraftment, primaryOutcomes measure: Time to neutrophil engraftment, primaryOutcomes measure: Time to platelet engraftment, primaryOutcomes measure: Incidence of transplant-related mortality, primaryOutcomes measure: Change in fetal hemoglobin(HbF) concentration over time, primaryOutcomes measure: Change in total hemoglobin(Hb) concentration over time, secondaryOutcomes measure: Chimerism level in Peripheral blood and bone marrow, secondaryOutcomes measure: Proportion of subjects achieving transfusion independence for at least 6 consecutive months, secondaryOutcomes measure: Proportion of subjects achieving fetal hemoglobin(HbF) increase≥2.0 g/dL, secondaryOutcomes measure: Proportion of subjects achieving fetal hemoglobin(HbF) increase≥7.0 g/dL, eligibilityModule sex: ALL, minimumAge: 7 Years, maximumAge: 35 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: The First Affiliated Hospital of Guangxi Medical University, city: Nanning, state: Guangxi, country: China, contacts name: Yongrong Lai, M.D., role: CONTACT, contacts name: Yongrong Lai, M.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 22.81667, lon: 108.31667, locations facility: Children's Hospital of Fudan University, city: Shanghai, state: Shanghai, country: China, contacts name: Xiaowen Zhai, M.D., role: CONTACT, contacts name: Xiaowen Zhai, M.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 31.22222, lon: 121.45806, locations facility: Ruijin Hospital Shanghai JiaoTong University School of Medicine, city: Shanghai, state: Shanghai, country: China, contacts name: Saijuan Chen, M.D., role: CONTACT, contacts name: Saijuan Chen, M.D., role: PRINCIPAL_INVESTIGATOR, contacts name: Weili Zhao, M.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06291935, orgStudyIdInfo id: VG901-2021 A, secondaryIdInfos id: EU CT: 2023-504383-42-00, type: OTHER, domain: EMA, briefTitle: Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-09-01, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: ViGeneron GmbH, class: INDUSTRY, descriptionModule briefSummary: The goal of this phase 1 clinical trial is to learn about the safety and efficacy of a gene therapy, VG901, in patients with a rare disorder of the eye called Retinitis Pigmentosa. The main questions the study aims to answer are:* What is the best tolerated dose and are there any side effects, in particular any inflammatory reactions post drug administration?* Are there any early signs of efficacy on visual function?Participants will be administered a single intravitreal dose of VG901 into the most affected eye through a syringe and followed up for a year to monitor safety and efficacy. There will be two cohorts of participants in this study. Study Cohort 1 will receive the low dose and Study Cohort 2 will receive the high dose as specified in the Protocol., conditionsModule conditions: Retinitis Pigmentosa, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 6, type: ESTIMATED, armsInterventionsModule interventions name: VG901, outcomesModule primaryOutcomes measure: Adverse Events (AEs) and Serious Adverse Events (SAEs), secondaryOutcomes measure: Physical Examination, secondaryOutcomes measure: Pulse rate, secondaryOutcomes measure: Blood pressure, secondaryOutcomes measure: Body temperature, secondaryOutcomes measure: Respiratory rate, secondaryOutcomes measure: Slit lamp examination, secondaryOutcomes measure: Fundus biomicroscopy, secondaryOutcomes measure: Optical coherence tomography (OCT), secondaryOutcomes measure: Fundus autofluorescence, secondaryOutcomes measure: Tonometry, secondaryOutcomes measure: Adeno-associated virus (AAV) spread, secondaryOutcomes measure: Immunopathology, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Center for Ophthalmology, University of Tuebingen, status: RECRUITING, city: Tuebingen, zip: 72076, country: Germany, contacts name: Andrea Rindtorff, role: CONTACT, geoPoint lat: 48.52266, lon: 9.05222, hasResults: False
protocolSection identificationModule nctId: NCT06291922, orgStudyIdInfo id: 853181, secondaryIdInfos id: R01HL166621, type: NIH, link: https://reporter.nih.gov/quickSearch/R01HL166621, briefTitle: Home-Based Exercise Program Using Mobile Technology After Left Ventricular Assist Device Implantation, acronym: MOVE-LVAD II, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2028-06, completionDateStruct date: 2028-06, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: University of Pennsylvania, class: OTHER, collaborators name: National Heart, Lung, and Blood Institute (NHLBI), descriptionModule briefSummary: The goal of this clinical trial is to evaluate the effects of a home-based exercise program using mobile technology on physical activity and capacity, frailty and muscle mass, and quality of life in patients with a newly implanted HeartMate 3 left ventricular assist device (HM3 LVAD). Researchers will compare the effects of an exercise intervention vs. usual care on physical activity and capacity, frailty and muscle mass, and quality of life., conditionsModule conditions: Heart Failure, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Exercise Intervention, interventions name: Usual Care, outcomesModule primaryOutcomes measure: Effects of exercise intervention on physical activity and capacity (step count), primaryOutcomes measure: Effects of exercise intervention on physical activity and capacity (distance), secondaryOutcomes measure: Effects of exercise intervention on frailty and muscle mass (frailty status), secondaryOutcomes measure: Effects of exercise intervention on frailty and muscle mass (muscle quantity), secondaryOutcomes measure: Effects of exercise intervention on quality of life, secondaryOutcomes measure: Cost-effectiveness of the exercise intervention vs. usual care, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06291883, orgStudyIdInfo id: CHUH112-REC2-008, briefTitle: Evaluation of KGR Prescriptions in Suppressing COVID-19 Infection., statusModule overallStatus: COMPLETED, startDateStruct date: 2023-02-09, primaryCompletionDateStruct date: 2023-04-18, completionDateStruct date: 2024-02-08, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: Sheng-Teng Huang, class: OTHER, descriptionModule briefSummary: These studies offer valuable insights into the potential development of KGR as a novel herbal-based preventive and therapeutic strategy against COVID-19., conditionsModule conditions: Coronavirus Disease 2019, conditions: Severe Acute Respiratory Syndrome Coronavirus 2 Infection, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 26, type: ACTUAL, armsInterventionsModule interventions name: Kang Guan Recipe (Treat), interventions name: Kang Guan Recipe (Placebo), outcomesModule primaryOutcomes measure: Serum Infection rate of pseudocells, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: China Medical University Hospital, city: Taichung, state: North District, zip: 404, country: Taiwan, geoPoint lat: 24.1469, lon: 120.6839, hasResults: False
protocolSection identificationModule nctId: NCT06291844, orgStudyIdInfo id: Cohort-Mata-2023-1, briefTitle: Ocular Trauma and COVID-19 in Indonesia, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-01-01, primaryCompletionDateStruct date: 2022-03-31, completionDateStruct date: 2023-06-01, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Prof. R. D. Kandou General Hospital, class: OTHER, descriptionModule briefSummary: Ocular injuries, a significant contributor to avoidable blindness globally, impact approximately 55 million individuals each year. Prompt initial treatment is vital for improving vision, yet the scarcity of skilled eye specialists often results in overcrowding at advanced medical centers. Moreover, the COVID-19 outbreak has introduced distinct factors into the management of ocular trauma. This research investigated the epidemiology of ocular injuries during the pandemic and offered observations on the distinctive hurdles and trends encountered., conditionsModule conditions: Ophthalmological Disorder, conditions: Ocular Injury, conditions: COVID-19, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 13, type: ACTUAL, outcomesModule primaryOutcomes measure: Ocular Trauma, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Ophthalmology, Prof. R. D. Kandou General Hospital - Faculty of Medicine, Sam Ratulangi University, city: Manado, state: North Sulawesi, country: Indonesia, geoPoint lat: 1.48218, lon: 124.84892, hasResults: False
protocolSection identificationModule nctId: NCT06291818, orgStudyIdInfo id: 2023-0917, briefTitle: Self-Adhering Magnetic Device to Treat Corneal Exposure, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-12-01, completionDateStruct date: 2025-04-01, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: University of Illinois at Chicago, class: OTHER, descriptionModule briefSummary: Paralytic lagophthalmos can be difficult to treat and manage. It has a host of causes and effects, one of which (for the latter) is exposure keratopathy. Untreated, this can lead to corneal ulceration, inflammation, and potentially blindness. Despite a variety of attempts at treating this complex condition, none have satisfactorily reduced complications ranging from ease of use to aesthetics. With improvement in magnetic technology, however, that may change. Barmettler et al (2014) have demonstrated preliminary success of externally affixed magnets in closing both model and patient eyelids. As such, we hypothesize that magnetic devices can be used to treat corneal exposure by controlling eyelid position., conditionsModule conditions: Paralytic Lagophthalmos, conditions: Corneal Exposure, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: temporary magnetic system for tarsorrhaphy (MST), primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 25, type: ESTIMATED, armsInterventionsModule interventions name: temporary magnetic system for tarsorrhaphy (MST), outcomesModule primaryOutcomes measure: Number of participants with success of a temporary magnetic system for tarsorrhaphy, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Illinois - Specialty Care Building, city: Chicago, state: Illinois, zip: 60612, country: United States, contacts name: Pete Setabutr, MD, role: CONTACT, phone: 312-996-9120, email: psetabut@uic.edu, geoPoint lat: 41.85003, lon: -87.65005, hasResults: False
protocolSection identificationModule nctId: NCT06291805, orgStudyIdInfo id: 1-10-72-189-23, briefTitle: Phenotyping and Characterization of wtATTR-CM (TRACE 1), statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-20, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Steen Hvitfeldt Poulsen, class: OTHER, collaborators name: Novo Nordisk A/S, descriptionModule briefSummary: Descriptive cross-sectional study on 100 consecutive ATTRwt-CM patients reflecting all NAC stages aiming primarily to investigate ATTRwt-CM patient's quality of life (QoL) measures and their relation to ATTRwt-CM severity. Secondarily aiming to investigate the possibility to measure misTTR and fragTTR in plasma and urine and to detect fragTTR in endomyocardial biopsies from ATTRwt-CM patients. To investigate whether misTTR and fragTTR levels are correlated with ATTRwt-CM severity., conditionsModule conditions: Transthyretin Amyloidosis, conditions: Transthyretin Amyloid Cardiomyopathy, conditions: Wild-Type Transthyretin-Related (ATTR)Amyloidosis, conditions: Quality of Life, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Investigation of cardiac amyloidosis severity in patients with Wild-type Transthyretin Amyloidosis Cardiomyopathy., primaryOutcomes measure: Investigation of the relations between cardiac amyloid severity and patient quality of life in patients with Wild-type Transthyretin Amyloidosis Cardiomyopathy., primaryOutcomes measure: Assessment of transthyretin and pathogenic fragments and relation to cardiac amyloid severity in patients with Wild-type Transthyretin Amyloidosis Cardiomyopathy, secondaryOutcomes measure: Validation of a new amyloid specific questionnaire (ATTR-QoL) in comparison with Kansas City Cardiomyopathy Questionnaire (KCCQ), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Aarhus University Hospital, status: RECRUITING, city: Aarhus, state: Arrhus N, zip: 8200, country: Denmark, contacts name: Sie Kronborg Fensman, role: CONTACT, phone: +45 30 48 88 85, email: siefensman@gmail.com, geoPoint lat: 56.15674, lon: 10.21076, hasResults: False
protocolSection identificationModule nctId: NCT06291792, orgStudyIdInfo id: FTR001, briefTitle: Otago Exercise Program Applied By Telerehabilitation, acronym: OEPABT, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-11-01, primaryCompletionDateStruct date: 2024-03-01, completionDateStruct date: 2024-03-01, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Sinop University, class: OTHER, descriptionModule briefSummary: The aim of this study is to examine the effects of Otago Exercise Program (OEP) on pain, walking speed, lower extremity muscle strength, fear of falling, anxiety, quality of life and balance with the telerehabilitation method in individuals with a history of falling, which is frequently seen in elderly individuals due to aging.45 people between the ages of 65 and 78 participated in the study. They were randomly divided into 3 groups as control, telerehabilitation otago exercise program (TOEG) and face-to-face otago exercise program (FOEG). 45 minutes of OEP was applied 3 times a week for 8 weeks. Pain, walking speed, lower extremity muscle strength, fear of falling, anxiety, quality of life, and balance were evaluated before the Otago Exercise Program, at the 4th week, at the 8th week, and 4 weeks after the end of the exercise program. Significance was evaluated at the p\<0.05 level in the study., conditionsModule conditions: Older People--Abuse of, conditions: Falling, conditions: Balance; Distorted, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: telerehabilitation otago exercise program, interventions name: face to face otago exercise program, outcomesModule primaryOutcomes measure: Numerical Pain Scale, primaryOutcomes measure: Walking Speed, primaryOutcomes measure: lower extremity muscle strength, primaryOutcomes measure: Fall effectiveness scale, primaryOutcomes measure: Beck anxiety scale, primaryOutcomes measure: Tinetti balance and walking test, primaryOutcomes measure: World Health Organization Quality of Life Scale:, eligibilityModule sex: ALL, minimumAge: 65 Years, maximumAge: 90 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Bahçeşehir University research application center, status: RECRUITING, city: Istanbul, country: Turkey, contacts name: Sefa Haktan Hatık, PhD, role: CONTACT, email: haktanhtk@gmail.com, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False